BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
Number Citing Articles
1 Lv WF, Liu KC, Lu D, Zhou CZ, Cheng DL, Xiao JK, Zhang XM, Zhang ZF. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. Cancer Manag Res 2018;10:4719-26. [PMID: 30410405 DOI: 10.2147/CMAR.S166527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
2 El Shorbagy S, abuTaleb F, Labib HA, Ebian H, Harb OA, Mohammed MS, Rashied HA, Elbana KA, Haggag R. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination. J Gastrointest Cancer 2021;52:269-79. [PMID: 32212089 DOI: 10.1007/s12029-020-00389-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther 2017;10:1403-12. [PMID: 28424556 DOI: 10.2147/OTT.S111681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Liu Q, Yang P, Tu K, Zhang H, Zheng X, Yao Y, Liu Q. TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res 2014;26:410-7. [PMID: 25232213 DOI: 10.3978/j.issn.1000-9604.2014.08.01] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
5 Shaaban S, Negm A, Ibrahim EE, Elrazak AA. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev 2014;8:246. [PMID: 25992234 DOI: 10.4081/oncol.2014.246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
6 Seo J, Yun JE, Kim SJ, Chun YS. Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment. Pflugers Arch 2022. [PMID: 35348849 DOI: 10.1007/s00424-022-02683-x] [Reference Citation Analysis]
7 Luo D, Wang Z, Wu J, Jiang C, Wu J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int 2014;2014:409272. [PMID: 25101278 DOI: 10.1155/2014/409272] [Cited by in Crossref: 49] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
8 Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol. 2017;12:201-209. [PMID: 27943153 DOI: 10.1007/s11523-016-0467-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
9 Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2016;3:31-36. [PMID: 27703962 DOI: 10.2147/jhc.s112537] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
10 Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. Med Oncol 2017;34:192. [PMID: 29098441 DOI: 10.1007/s12032-017-1040-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]